Disease Markers

Estrogen Receptors’ Isoforms in Cancer and Other Pathologies: An Update


Publishing date
01 Jun 2020
Status
Open
Submission deadline
17 Jan 2020

Lead Editor

1“Vinca” Institute of Nuclear Sciences, Belgrade, Serbia

2King's College London, Rayne Institute, London, UK

3Visuals Consulting, Utrecht, Netherlands

4Scientific Affairs Manager at Sobi - Swedish Orphan Biovitrum AB, Stockholm, Sweden


Estrogen Receptors’ Isoforms in Cancer and Other Pathologies: An Update


Call for papers

This Issue is now open for submissions.

Papers are published upon acceptance, regardless of the Special Issue publication date.

 Submit to this Special Issue

Description

Three decades on from the first reports of numerous isoforms and splice variants of estrogen receptor alpha (ERα) and later of estrogen receptor beta (ERβ), both receptors still present a very open issue. It is not pretentious to say that there is a “mystery” regarding their biological role and clinical significance, especially in endocrine related cancers. While ERα is a well-established prognostic marker for responsiveness to endocrine therapy in breast cancer, a significant number of ERα-positive patients fail to respond to therapy or develop resistance over time. Moreover, the role of ERα and ERβ is implicated in other types of cancer (ovarian, colorectal, prostate, endometrial, and sarcomas), as well as in osteoporosis, neurodegenerative diseases, cardiovascular disease, insulin resistance, lupus erythematosus, endometriosis, and obesity.

The intriguing question today is whether the ERα and ERβ, their isoforms, and internal-exon-deleted splice variants are potential disease markers, especially in the triple negative breast cancer subgroup for which adequate treatment regimens are not available. Moreover, the role of ERβ as disease marker is often implicated in nonendocrine cancers and different nonmalignant pathologies.

What can we learn about them from earlier studies with competitive RT-PCR, compared to qRT-PCR till chip-based methodology? Do all of the splice variants exist at protein level? How do they influence the activity of full length (wild type) proteins ERα and ERβ? Are they potential disease markers?

The aim of this issue is to summarize the state of the art in biological function and clinical potential of the ERs “pool” in normal and malignant cells. Research articles as well as reviews are welcome.

Potential topics include but are not limited to the following:

  • The emergent need for precise nomenclature of different N-terminal isoforms of ERα and C-terminal isoforms of ERβ, as well as for internal-exon-deleted splice variants
  • Experimental evidence that internal-exon-deleted splice variants are translated into proteins
  • Expression profiling of isoforms and variants in cancers and other pathologies
  • Biological role of isoforms and the splice variants of ERα and ERβ
  • The clinical importance of isoforms and splice variants of the ERα and ERβ in terms of prediction, prognosis, and therapeutical potential
Disease Markers
 Journal metrics
Acceptance rate34%
Submission to final decision87 days
Acceptance to publication43 days
CiteScore2.640
Impact Factor2.761

You are browsing a BETA version of Hindawi.com. Click here to switch back to the original design.